• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作用模式拟合在确定激动剂相对效价中的应用和局限性。

Applications and limitations of fitting of the operational model to determine relative efficacies of agonists.

机构信息

Institute of Physiology CAS, 142 20, Prague, Czech Republic.

Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, 55455, USA.

出版信息

Sci Rep. 2019 Mar 15;9(1):4637. doi: 10.1038/s41598-019-40993-w.

DOI:10.1038/s41598-019-40993-w
PMID:30874590
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6420642/
Abstract

Proper determination of agonist efficacy is essential in the assessment of agonist selectivity and signalling bias. Agonist efficacy is a relative term that is dependent on the system in which it is measured, especially being dependent on receptor expression level. The operational model (OM) of functional receptor agonism is a useful means for the determination of agonist functional efficacy using the maximal response to agonist and ratio of agonist functional potency to its equilibrium dissociation constant (K) at the active state of the receptor. However, the functional efficacy parameter τ is inter-dependent on two other parameters of OM; agonist's K and the highest response that could be evoked in the system by any stimulus (E). Thus, fitting of OM to functional response data is a tricky process. In this work we analyse pitfalls of fitting OM to experimental data and propose a rigorous fitting procedure where K and E are derived from half-efficient concentration of agonist and apparent maximal responses obtained from a series of functional response curves. Subsequently, OM with fixed K and E is fitted to functional response data to obtain τ. The procedure was verified at M and M muscarinic receptors fused with the G G-protein α-subunit. The procedure, however, is applicable to any receptor-effector system.

摘要

正确确定激动剂的效能在评估激动剂的选择性和信号转导偏倚方面至关重要。激动剂效能是一个相对的术语,取决于测量的系统,特别是受体表达水平。功能性受体激动作用的操作模型(OM)是一种有用的方法,可通过测量激动剂的最大反应和激动剂在受体活性状态下的功能效价与平衡解离常数(K)的比值来确定激动剂的功能效能。然而,功能效能参数τ与 OM 的另外两个参数密切相关;激动剂的 K 和任何刺激在系统中可以引起的最高反应(E)。因此,将 OM 拟合到功能响应数据是一个棘手的过程。在这项工作中,我们分析了将 OM 拟合到实验数据时的陷阱,并提出了一种严格的拟合程序,其中 K 和 E 是从激动剂的半有效浓度和从一系列功能响应曲线获得的表观最大响应中得出的。随后,使用固定的 K 和 E 的 OM 拟合功能响应数据以获得τ。该程序在与 G 蛋白α亚基融合的 M 和 M 毒蕈碱受体上进行了验证。然而,该程序适用于任何受体-效应器系统。

相似文献

1
Applications and limitations of fitting of the operational model to determine relative efficacies of agonists.作用模式拟合在确定激动剂相对效价中的应用和局限性。
Sci Rep. 2019 Mar 15;9(1):4637. doi: 10.1038/s41598-019-40993-w.
2
Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.刺激放大、效能与作用模型。第二部分——三元复合物占据机制
J Theor Biol. 1999 Jun 7;198(3):347-74. doi: 10.1006/jtbi.1999.0920.
3
The operational model of allosteric modulation of pharmacological agonism.变构调节药理学激动作用的作用模式。
Sci Rep. 2020 Sep 2;10(1):14421. doi: 10.1038/s41598-020-71228-y.
4
Interactions of agonists with M2 and M4 muscarinic receptor subtypes mediating cyclic AMP inhibition.激动剂与介导环磷酸腺苷抑制作用的M2和M4毒蕈碱受体亚型的相互作用。
Mol Pharmacol. 1991 Dec;40(6):1014-22.
5
A critical re-evaluation of the slope factor of the operational model of agonism: When to exponentiate operational efficacy.激动剂作用模式的斜率因子的关键性再评价:何时对作用效力取指数。
Sci Rep. 2023 Oct 16;13(1):17587. doi: 10.1038/s41598-023-45004-7.
6
Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines.药理学无效实验的改进模型:克隆细胞系中稳定表达的重组D1A多巴胺受体的药物效能计算
Neuropharmacology. 1996 May;35(5):549-70. doi: 10.1016/0028-3908(96)84625-9.
7
New methods for determining dissociation constants of agonist-receptor complexes.测定激动剂-受体复合物解离常数的新方法。
Eur J Pharmacol. 1996 May 15;303(3):235-46. doi: 10.1016/0014-2999(96)00075-1.
8
Efficacy. I: A new method for estimating relative efficacy of full agonists via a newly defined efficacy related parameter.功效。I:一种通过新定义的与功效相关的参数来估计完全激动剂相对功效的新方法。
Eur J Pharmacol. 1997 Feb 12;320(2-3):223-31. doi: 10.1016/s0014-2999(96)00899-0.
9
Determination of agonist dissociation constants in isolated vasculature: equivalence of estimates obtained by the method of partial irreversible receptor inactivation and a novel application of the operational model of pharmacological agonism.离体血管系统中激动剂解离常数的测定:通过部分不可逆受体失活方法获得的估计值与药理学激动作用操作模型的新应用的等效性
Life Sci. 1990;47(20):1867-74. doi: 10.1016/0024-3205(90)90290-8.
10
Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.从化学角度量化生物活性:描述药物效应的药理学入门知识。
ACS Chem Biol. 2009 Apr 17;4(4):249-60. doi: 10.1021/cb800299s. Epub 2009 Feb 4.

引用本文的文献

1
Quantification of signal amplification for receptors: the /EC ratio of full agonists as a gain parameter.受体信号放大的定量分析:以完全激动剂的/EC比值作为增益参数。
Front Pharmacol. 2025 Apr 8;16:1541872. doi: 10.3389/fphar.2025.1541872. eCollection 2025.
2
Structural Insights into Partial Activation of the Prototypic G Protein-Coupled Adenosine A Receptor.典型G蛋白偶联腺苷A受体部分激活的结构见解
ACS Pharmacol Transl Sci. 2024 Apr 29;7(5):1415-1425. doi: 10.1021/acsptsci.4c00051. eCollection 2024 May 10.
3
Agonist-selective activation of individual G-proteins by muscarinic receptors.

本文引用的文献

1
Synthesis of novel and functionally selective non-competitive muscarinic antagonists as chemical probes.新型功能选择性非竞争性毒蕈碱拮抗剂的合成作为化学探针。
Chem Biol Drug Des. 2018 Jan;91(1):93-104. doi: 10.1111/cbdd.13059. Epub 2017 Jul 17.
2
Allosteric coupling from G protein to the agonist-binding pocket in GPCRs.G蛋白偶联受体中从G蛋白到激动剂结合口袋的变构偶联。
Nature. 2016 Jul 7;535(7610):182-6. doi: 10.1038/nature18324. Epub 2016 Jun 29.
3
Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor.
毒蕈碱型乙酰胆碱受体对单个 G 蛋白的激动剂选择性激活。
Sci Rep. 2024 Apr 26;14(1):9652. doi: 10.1038/s41598-024-60259-4.
4
A critical re-evaluation of the slope factor of the operational model of agonism: When to exponentiate operational efficacy.激动剂作用模式的斜率因子的关键性再评价:何时对作用效力取指数。
Sci Rep. 2023 Oct 16;13(1):17587. doi: 10.1038/s41598-023-45004-7.
5
Quantification of receptor binding from response data obtained at different receptor levels: a simple individual sigmoid fitting and a unified SABRE approach.从不同受体水平获得的反应数据中定量受体结合:一种简单的个体 S 型拟合和一种统一的 SABRE 方法。
Sci Rep. 2022 Nov 6;12(1):18833. doi: 10.1038/s41598-022-23588-w.
6
Cancer-Associated Mutations of the Adenosine A Receptor Have Diverse Influences on Ligand Binding and Receptor Functions.腺苷 A 受体的癌症相关突变对配体结合和受体功能具有多种影响。
Molecules. 2022 Jul 22;27(15):4676. doi: 10.3390/molecules27154676.
7
Fusion with Promiscuous Gα Subunit Reveals Signaling Bias at Muscarinic Receptors.与混杂 Gα 亚基融合揭示毒蕈碱受体的信号转导偏向性。
Int J Mol Sci. 2021 Sep 18;22(18):10089. doi: 10.3390/ijms221810089.
8
Employing the Operational Model to Measure System-Independent OTR Efficacy.运用操作模型衡量与系统无关的 OTR 疗效。
Methods Mol Biol. 2022;2384:201-220. doi: 10.1007/978-1-0716-1759-5_12.
9
Novel M -selective, G -biased agonists of muscarinic acetylcholine receptors.新型 M 型选择性、G 蛋白偏向性毒蕈碱型乙酰胆碱受体激动剂。
Br J Pharmacol. 2020 May;177(9):2073-2089. doi: 10.1111/bph.14970. Epub 2020 Feb 15.
对影响μ-阿片受体偏向激动作用观察结果的因素进行系统分析。
Biochem Pharmacol. 2016 Aug 1;113:70-87. doi: 10.1016/j.bcp.2016.05.014. Epub 2016 Jun 7.
4
Theoretical Aspects of GPCR-Ligand Complex Pharmacology.G 蛋白偶联受体配体复合物药理学的理论方面。
Chem Rev. 2017 Jan 11;117(1):4-20. doi: 10.1021/acs.chemrev.5b00561. Epub 2016 Feb 9.
5
Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody.激活的胰岛素受体的差异途径偶联通过 XMetA(一种变构部分激动剂抗体)驱动信号选择性。
J Pharmacol Exp Ther. 2015 Apr;353(1):35-43. doi: 10.1124/jpet.114.221309. Epub 2015 Jan 22.
6
Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.对M1毒蕈碱型乙酰胆碱受体变构结构-功能关系的机制性见解。
J Biol Chem. 2014 Nov 28;289(48):33701-11. doi: 10.1074/jbc.M114.604967. Epub 2014 Oct 17.
7
Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.M1 毒蕈碱型乙酰胆碱受体变构调节的分子决定因素。
J Biol Chem. 2014 Feb 28;289(9):6067-79. doi: 10.1074/jbc.M113.539080. Epub 2014 Jan 17.
8
Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.定量分析临床相关β2-肾上腺素能受体配体的配体偏向:对药物分类学的影响。
Mol Pharmacol. 2014 Mar;85(3):492-509. doi: 10.1124/mol.113.088880. Epub 2013 Dec 23.
9
Signalling bias in new drug discovery: detection, quantification and therapeutic impact.新药发现中的信号偏倚:检测、定量和治疗影响。
Nat Rev Drug Discov. 2013 Mar;12(3):205-16. doi: 10.1038/nrd3954. Epub 2012 Feb 15.
10
New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.7TM 受体药理学功效的新概念:IUPHAR 综述 2.
Br J Pharmacol. 2013 Feb;168(3):554-75. doi: 10.1111/j.1476-5381.2012.02223.x.